Drug Database · Clinicians

Cilnidipine

Brands (4) Cildine, Nulong 10, Nulong 20…Show all

Selective calcium channel blocker (dihydropyridine derivative); Calcium channel blocker (dihydropyridine derivative) PH FDA category

Rx · Prescription drug5 PH productsVAT-exempt Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Contraindications

  • Pregnancy or possible pregnancy
renalcarematters.com, reviewed

Dosing: Adult

  • Hypertension: 5 to 10 mg once daily after breakfast; up to 20 mg once daily; severe hypertension 10 to 20 mg once daily
renalcarematters.com, reviewed

Dosing: Altered kidney function

Cilnidipine is a dihydropyridine calcium-channel blocker (L- and N-type) metabolized by CYP3A4 with no unchanged drug in urine. In patients with serum creatinine 1.5 to 3.1 mg/dL its levels were the same as with normal kidney function, and the Japanese insert sets no kidney dose change. It has no US FDA label.

Kidney function measure: Japanese kidney data are by serum creatinine (1.5 to 3.1 mg/dL); bands shown on creatinine clearance (CrCl) by judgment.

Show full dosing details
CrCl ≥60 mL/min
Usual: 5 to 10 mg once daily after breakfast; up to 20 mg once daily (PMDA insert). Older adults: start 5 mg.
CrCl 30–59 mL/min
No kidney dose change in the Japanese insert. A 10 mg dose in patients with serum creatinine 1.5 to 3.1 mg/dL gave levels no different from normal kidney function, with no accumulation over 7 days (PMDA insert).
CrCl 15–29 mL/min
No kidney dose change in the Japanese insert. A 10 mg dose in patients with serum creatinine 1.5 to 3.1 mg/dL gave levels no different from normal kidney function, with no accumulation over 7 days (PMDA insert).
CrCl <15 mL/min (not on dialysis)
Not studied below the creatinine range tested (1.5 to 3.1 mg/dL). Hepatically cleared, so a change is not expected; titrate from 5 mg.
Hemodialysis (intermittent)
Not studied in dialysis (PMDA insert). Hepatically cleared; start low and titrate.
Peritoneal dialysis
Not studied.
CRRT
Not studied.
  • Dialyzable? Not stated (99.3% protein-bound).
  • Monitoring Blood pressure (avoid excessive lowering in older adults); liver tests if symptoms (hepatic dysfunction, jaundice); platelets (thrombocytopenia under 0.1%) (PMDA insert).
Children (kidney dosing)
eGFR ≥60
Not established in children; kidney dosing not applicable.
eGFR 30–59
Not established in children; kidney dosing not applicable.
eGFR 15–29
Not established in children; kidney dosing not applicable.
eGFR <15 (not on dialysis)
Not established in children; kidney dosing not applicable.
Hemodialysis (intermittent)
Not established in children; kidney dosing not applicable.
Peritoneal dialysis
Not established in children; kidney dosing not applicable.
CRRT
Not established in children; kidney dosing not applicable.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

Source: PMDA (Japan) product information (June 2023). This generic has no US FDA label.

Dosing: Pediatric

Approved ages
No pediatric trials (PMDA insert).
Usual dose
Not established.

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed

Dosage forms

Philippines

  • Film-coated tablet: 10 mg, 20 mg
  • Tablet: 5 mg

Registered products in the Philippines

5 products registered with the Food and Drug Administration (FDA) Philippines list Cilnidipine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products5
Philippine FDA-registered products for Cilnidipine
Package insert
CildineCilnidipine
10mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines, Inc.Importer: Ajanta Pharma Philippines Inc..
DR-XY47574
Dec 1, 2026
CildineCilnidipine
20mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Ajanta Pharma LimitedIndia
Ajanta Pharma Philippines, Inc.Importer: Ajanta Pharma Philippines Inc..
DR-XY47575
Dec 1, 2026
Nulong 10Cilnidipine
10 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 3 blister packs x 10 tablets)
RxVAT-exempt
Micro Labs LimitedIndia
Brown & Burk Phils., Inc.
DR-XY49400
May 22, 2030
Nulong 20Cilnidipine
20 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 3 blister packs x 10 tablets)
RxVAT-exempt
Micro Labs LimitedIndia
Brown & Burk Phils., Inc.
DR-XY49401
May 22, 2030
Nulong 5Cilnidipine
5 mg TabletAlu-Alu Blister Pack x 10's (Box of 3 blister packs x 10 tablets)
RxVAT-exempt
Micro Labs LimitedIndia
Brown & Burk Phils., Inc.
DR-XY49399
May 22, 2030

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Drug interactions

Drug or classSeverityEffectWhat to do
Azole antifungals (itraconazole, miconazole), cimetidine, grapefruit juiceAdjust or monitorHigher cilnidipine levels.Monitor blood pressure; avoid grapefruit.
RifampicinAdjust or monitorLower cilnidipine levels.Monitor blood pressure.
DigoxinAdjust or monitorCalcium-channel blockers can raise digoxin levels.Watch for digoxin toxicity.
Other antihypertensivesMinorAdditive blood-pressure lowering.Adjust doses.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed

Adverse reactions

Common

  • Dizziness, headache
  • Flushing, palpitations
  • Edema

Serious

  • Hepatic dysfunction, jaundice
  • Thrombocytopenia
renalcarematters.com, reviewed

Monitoring parameters

  • Blood pressure (avoid excessive lowering in older adults); liver tests if symptoms (hepatic dysfunction, jaundice); platelets (thrombocytopenia under 0.1%) (PMDA insert). Kidney
  • Blood pressure
  • Liver tests if symptoms
renalcarematters.com, reviewed

Pharmacokinetics

Key PK parameters

Time to peakAbout 2.5 to 2.8 hours
Half-lifeAbout 7 hours single dose (5.2 hours on day 1 to 8.1 hours on day 7 with repeat dosing)
Half-life in kidney failure (ESKD) kidneyUnchanged at serum creatinine 1.5 to 3.1 mg/dL
Protein binding99.3%
Metabolism (CYP, transporters)Mainly CYP3A4, some CYP2C19
Renal excretion kidneyNo unchanged drug in urine; metabolites 5.2%
Dialyzability kidneyNot stated
renalcarematters.com, reviewed

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Pharmaceuticals and Medical Devices Agency (Japan). Cilnidipine tablets "SAWAI" package insert [PMDA (Japan) product information, June 2023; no US FDA label]. https://www.pmda.go.jp/PmdaSearch/bookSearch/01/04987080906407
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. Sawai Pharmaceutical Co., Ltd. (2023). Cilnidipine tablets 5 mg, 10 mg and 20 mg "SAWAI" [Japanese package insert, 1st edition, revised June 2023]. Pharmaceuticals and Medical Devices Agency (PMDA), Japan. https://www.pmda.go.jp/PmdaSearch/bookSearch/01/04987080906407

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .